Key Insights

Highlights

Treatment Research

1 treatments under study, led by Infliximab

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 1/2 (1)

Trial Status

Withdrawn1

Clinical Trials (1)

Showing 1 of 1 trials
NCT02126020Phase 1/2Withdrawn

Topical Infliximab in Autoimmune Eyes With Keratoprosthesis

Showing all 1 trials

Research Network

Common Treatments

  • Infliximab1

Active Sponsors

  • Fonds de recherche en ophtalmologie de l'Université de Montréal1
  • James Chodosh, MD, MPH1
  • Massachusetts Eye and Ear Infirmary1

Top Investigators

Related Conditions

  • Stevensjohnson Syndrome1
  • Mucous Membrane Pemphigoid1

Activity Timeline